Regeneron Pharmaceuticals, Inc.
REGNNASDAQHealthcare● Active
$635.45
+$6.72(+1.07%)
Market Cap$65.5B
P/E Ratio—
52W High$821.11
52W Low$476.49
Regeneron Pharmaceuticals, Inc. (REGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
REGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$9.47
Est. $8.91 · +6.3%
Revenue
$3.61B
Est. $3.48B · +3.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
REGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $10.85 | — | — | — | $3.82B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | $8.91 | $9.47 | +6.3% | $3.61B | $3.48B | +3.6% |
| ▲ Q1 FY2026 | Jan 30, 2026 | $10.74 | $11.44 | +6.5% | $3.88B | $3.81B | +1.9% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $9.65 | $11.83 | +22.6% | $3.75B | $3.59B | +4.5% |
| ▲ Q3 FY2025 | Aug 1, 2025 | $8.43 | $12.89 | +52.9% | $3.68B | $3.29B | +11.8% |
| ▼ Q2 FY2025 | Apr 29, 2025 | $8.62 | $8.22 | -4.6% | $3.03B | $3.25B | -6.8% |
| ▲ Q1 FY2025 | Feb 4, 2025 | $11.21 | $12.07 | +7.7% | $3.79B | $3.74B | +1.3% |
| ▲ Q4 FY2024 | Oct 31, 2024 | $11.69 | $12.46 | +6.6% | $3.72B | $3.67B | +1.3% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$10.85
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$9.47
EPS Est.
$8.91
EPS Surpr.
+6.3%
Revenue
$3.61B
Q1 FY2026
Jan 30, 2026Beat
EPS Actual
$11.44
EPS Est.
$10.74
EPS Surpr.
+6.5%
Revenue
$3.88B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$11.83
EPS Est.
$9.65
EPS Surpr.
+22.6%
Revenue
$3.75B
Q3 FY2025
Aug 1, 2025Beat
EPS Actual
$12.89
EPS Est.
$8.43
EPS Surpr.
+52.9%
Revenue
$3.68B
Q2 FY2025
Apr 29, 2025Miss
EPS Actual
$8.22
EPS Est.
$8.62
EPS Surpr.
-4.6%
Revenue
$3.03B
Q1 FY2025
Feb 4, 2025Beat
EPS Actual
$12.07
EPS Est.
$11.21
EPS Surpr.
+7.7%
Revenue
$3.79B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
$12.46
EPS Est.
$11.69
EPS Surpr.
+6.6%
Revenue
$3.72B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $15.19 | $17.26 | $19.56 | 6 |
| Q3 FY2027 | $12.68 | $14.41 | $16.33 | 6 |
| Q2 FY2027 | $11.67 | $13.26 | $15.03 | 6 |
| Q1 FY2027 | $10.12 | $11.50 | $13.04 | 6 |
| Q4 FY2026 | $11.50 | $13.06 | $14.81 | 10 |
| Q3 FY2026 | $9.75 | $13.08 | $15.07 | 15 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.6B | $5.0B | $5.6B | 6 |
| Q3 FY2027 | $4.1B | $4.5B | $5.0B | 6 |
| Q2 FY2027 | $3.9B | $4.3B | $4.7B | 6 |
| Q1 FY2027 | $3.6B | $3.9B | $4.3B | 6 |
| Q4 FY2026 | $3.9B | $4.3B | $4.8B | 6 |
| Q3 FY2026 | $3.8B | $4.2B | $4.5B | 13 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +6.3% | $731.77 | $686.36 | -6.21% |
| ▲ Q1 FY2026 | Jan 30, 2026 | +6.5% | $749.44 | $741.45 | -1.07% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +22.6% | $585.31 | $654.48 | +11.82% |
| ▲ Q3 FY2025 | Aug 1, 2025 | +52.9% | $545.46 | $558.87 | +2.46% |
| ▼ Q2 FY2025 | Apr 29, 2025 | -4.6% | $610.86 | $568.91 | -6.87% |
| ▲ Q1 FY2025 | Feb 4, 2025 | +7.7% | $666.85 | $697.05 | +4.53% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +6.6% | $922.79 | $838.20 | -9.17% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +8.9% | $1,079.19 | $1,093.14 | +1.29% |
Q2 FY2026-6.21%
Report Date
Apr 29, 2026
EPS Beat/Miss
+6.3%
Price Before
$731.77
Price After
$686.36
Q1 FY2026-1.07%
Report Date
Jan 30, 2026
EPS Beat/Miss
+6.5%
Price Before
$749.44
Price After
$741.45
Q4 FY2025+11.82%
Report Date
Oct 28, 2025
EPS Beat/Miss
+22.6%
Price Before
$585.31
Price After
$654.48
Q3 FY2025+2.46%
Report Date
Aug 1, 2025
EPS Beat/Miss
+52.9%
Price Before
$545.46
Price After
$558.87
Q2 FY2025-6.87%
Report Date
Apr 29, 2025
EPS Beat/Miss
-4.6%
Price Before
$610.86
Price After
$568.91
Q1 FY2025+4.53%
Report Date
Feb 4, 2025
EPS Beat/Miss
+7.7%
Price Before
$666.85
Price After
$697.05
Q4 FY2024-9.17%
Report Date
Oct 31, 2024
EPS Beat/Miss
+6.6%
Price Before
$922.79
Price After
$838.20
Q3 FY2024+1.29%
Report Date
Aug 1, 2024
EPS Beat/Miss
+8.9%
Price Before
$1,079.19
Price After
$1,093.14
Avg Beat Reaction+0.52%
Avg Miss Reaction-6.87%
Beat Rate7 / 8 quarters
Largest Move+11.82% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: REGN ends December
Regeneron Pharmaceuticals, Inc. (REGN) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $9.47 — beating the analyst consensus of $8.91 by +6.3%. REGN has beaten EPS estimates for 4 consecutive quarters. The next REGN earnings date is expected around September 1, 2026.
Each quarter, investors track REGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. REGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
REGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
REGN earnings · 5 questionsRegeneron Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. REGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; REGN historically reports after market close (AMC).
REGN earnings datewhen is REGN earningsREGN next earnings datewhen does REGN report earningsREGN earnings calendar
▸ Source: FMP · Regeneron Pharmaceuticals, Inc. SEC filings · US GAAP · Regeneron Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026